Filing Flows › Keros Therapeutics (KROS) › Q3 2026 › vs Q3 2025
Keros Therapeutics (KROS) Q3 2026 vs Q3 2025 (year over year)
Keros Therapeutics's revenue rose $25.9M (+183%) from $14.1M in Q3 2025 to $40.0M in Q3 2026. Operating margin 32.0% against -108.9% (+141.0 pts).
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 32.0% | -108.9% | +141.0 pts |
| Net margin | 35.4% | -51.5% | +86.9 pts |
| Free cash flow margin | 8.3% | 22.1% | -13.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $40.0M | $14.1M | $25.9M | +183% |
| Other income, net | $2.1M | $6.7M | −$4.6M | -68% |
| Operating profit | $12.8M | −$15.4M | $28.2M | — |
| Costs & expenses | $27.2M | $29.5M | −$2.3M | -8% |
| Pre-tax earnings | $14.9M | −$8.7M | $23.6M | — |
| Net earnings | $14.2M | −$7.3M | $21.4M | — |
| Income tax | $772K | −$1.4M | $2.2M | — |
| Operating cash sources | $18.7M | −$2.9M | $21.6M | — |
| Depreciation | $384K | $395K | −$11K | -3% |
| Share-based compensation | $4.2M | $4.0M | $217K | +5% |
| Working capital & other | $15.3M | −$6.1M | $21.5M | — |
| Operating cash flow | $3.4M | $3.2M | $141K | +4% |
| Free cash flow (OCF − capex) | $3.3M | $3.1M | $214K | +7% |
| Capital expenditures | $59K | $132K | −$73K | -55% |
Questions
How much did Keros Therapeutics's revenue grow year over year in Q3 2026?
Keros Therapeutics's revenue rose $25.9M (+183%) from $14.1M in Q3 2025 to $40.0M in Q3 2026. Operating margin 32.0% against -108.9% (+141.0 pts).